Passa al contenuto
Merck

Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.

Genome biology (2014-08-28)
Rosalie Fisher, Stuart Horswell, Andrew Rowan, Maximilian P Salm, Elza C de Bruin, Sakshi Gulati, Nicholas McGranahan, Mark Stares, Marco Gerlinger, Ignacio Varela, Andrew Crockford, Francesco Favero, Virginie Quidville, Fabrice André, Carolina Navas, Eva Grönroos, David Nicol, Steve Hazell, David Hrouda, Tim O'Brien, Nik Matthews, Ben Phillimore, Sharmin Begum, Adam Rabinowitz, Jennifer Biggs, Paul A Bates, Neil Q McDonald, Gordon Stamp, Bradley Spencer-Dene, James J Hsieh, Jianing Xu, Lisa Pickering, Martin Gore, James Larkin, Charles Swanton
ABSTRACT

Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution. We perform whole exome sequencing on four clear cell renal cell carcinomas removed from both kidneys of a patient with a germline VHL mutation. We report that tumors arising in this context are clonally independent and harbour distinct secondary events exemplified by loss of chromosome 3p, despite an identical genetic background and tissue microenvironment. We propose that divergent mutational and copy number anomalies are contingent upon the nature of 3p loss of heterozygosity occurring early in tumorigenesis. However, despite distinct 3p events, genomic, proteomic and immunohistochemical analyses reveal evidence for convergence upon the PI3K-AKT-mTOR signaling pathway. Four germline tumors in this young patient, and in a second, older patient with VHL syndrome demonstrate minimal intra-tumor heterogeneity and mutational burden, and evaluable tumors appear to follow a linear evolutionary route, compared to tumors from patients with sporadic clear cell renal cell carcinoma. In tumors developing from a germline VHL mutation, the evolutionary principles of contingency and convergence in tumor development are complementary. In this small set of patients with early stage VHL-associated tumors, there is reduced mutation burden and limited evidence of intra-tumor heterogeneity.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Metanolo, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Metanolo, ACS reagent, ≥99.8%
Sigma-Aldrich
Metanolo, HPLC Plus, ≥99.9%
Sigma-Aldrich
Glicina, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Glicina, suitable for electrophoresis, ≥99%
Sigma-Aldrich
MOPS, ≥99.5% (titration)
Sigma-Aldrich
Metanolo, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
Glicina, BioUltra, for molecular biology, ≥99.0% (NT)
Sigma-Aldrich
Metanolo, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
MOPS, BioPerformance Certified, suitable for cell culture, ≥99.5% (titration)
Sigma-Aldrich
Metanolo, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
Glicina, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Sigma-Aldrich
Metanolo, ACS reagent, ≥99.8%
Sigma-Aldrich
Metanolo, BioReagent, ≥99.93%
SAFC
Glicina
Sigma-Aldrich
Metanolo, Absolute - Acetone free
USP
Metanolo, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
MOPS, BioXtra, ≥99.5% (titration)
Sigma-Aldrich
Metanolo, ACS reagent, ≥99.8%
USP
Glicina, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Glicina, BioXtra, ≥99% (titration)
Sigma-Aldrich
Mechlorethamine hydrochloride, 98%
Sigma-Aldrich
Glicina, 99%, FCC
Supelco
Metanolo, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Metanolo, analytical standard
Sigma-Aldrich
Metanolo, NMR reference standard
Sigma-Aldrich
Glicina, ACS reagent, ≥98.5%
Sigma-Aldrich
MOPS, anhydrous, free-flowing, Redi-Dri, ≥99.5%
Sigma-Aldrich
Methanol solution, NMR reference standard, 4% in methanol-d4 (99.8 atom % D), NMR tube size 3 mm × 8 in.
Sigma-Aldrich
Methanol-12C, 99.95 atom % 12C